Zhang, Z.; Morrison, D.; Lu, L.; Singh, M.; Yan, J.; Leighl, N.; Laurie, S.A.; Hotte, S.
First-in-Human Phase I Clinical Trial of SLC-391, a Novel and Selective AXL Inhibitor, in Patients with Advanced Solid Tumours. Pharmaceuticals 2025, 18, 1898.
https://doi.org/10.3390/ph18121898
AMA Style
Zhang Z, Morrison D, Lu L, Singh M, Yan J, Leighl N, Laurie SA, Hotte S.
First-in-Human Phase I Clinical Trial of SLC-391, a Novel and Selective AXL Inhibitor, in Patients with Advanced Solid Tumours. Pharmaceuticals. 2025; 18(12):1898.
https://doi.org/10.3390/ph18121898
Chicago/Turabian Style
Zhang, Zaihui, Donna Morrison, Liang Lu, Madhu Singh, Jun Yan, Natasha Leighl, Scott A. Laurie, and Sebastien Hotte.
2025. "First-in-Human Phase I Clinical Trial of SLC-391, a Novel and Selective AXL Inhibitor, in Patients with Advanced Solid Tumours" Pharmaceuticals 18, no. 12: 1898.
https://doi.org/10.3390/ph18121898
APA Style
Zhang, Z., Morrison, D., Lu, L., Singh, M., Yan, J., Leighl, N., Laurie, S. A., & Hotte, S.
(2025). First-in-Human Phase I Clinical Trial of SLC-391, a Novel and Selective AXL Inhibitor, in Patients with Advanced Solid Tumours. Pharmaceuticals, 18(12), 1898.
https://doi.org/10.3390/ph18121898
